Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Regenerative Inducing Medicine®Redasemtide
Applicable field (uses covered by this announcement)
Epidermolysis BullosaAcute ischemic strokeSkin regenerationNeural stem cell regeneration
Relationship between the counterparty and the company
StemRIM Inc.4599
Relationship with the Company
Joint research partner. Capital and personnel relationships: Not disclosed.
CounterpartyOsaka University
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Nature Communications
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative Inducing Medicine®, Redasemtide |
| Counterparty | Osaka University |
| Relationship with the Company | Joint research partner. Capital and personnel relationships: Not disclosed. |
| Applicable area | Epidermolysis Bullosa, Acute ischemic stroke, Skin regeneration, Neural stem cell regeneration |
| Source | Nature Communications |
Items this document does not state (13)
Counterparty overviewContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Based on the concept that tissue regeneration recapitulates tissue development, StemRIM and Osaka University studied the role of mesenchymal cells in embryonic skin development to further elucidate the mechanism of action of tissue regeneration induced by regenerative induction medicines.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.